BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12091003)

  • 1. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Hamon M
    Lancet; 2002 Jun; 359(9324):2199-200; author reply 2203-4. PubMed ID: 12091003
    [No Abstract]   [Full Text] [Related]  

  • 2. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Cruickshank JM
    Lancet; 2002 Jun; 359(9324):2200-1; author reply 2203-4. PubMed ID: 12091004
    [No Abstract]   [Full Text] [Related]  

  • 3. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Fuchs FD
    Lancet; 2002 Jun; 359(9324):2203; author reply 2203-4. PubMed ID: 12091010
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
    Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Cockcroft JR; Brown MJ
    Lancet; 2002 Jun; 359(9324):2202; author reply 2203-4. PubMed ID: 12091008
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Kidney protection leads to heart protection, too].
    MMW Fortschr Med; 2006 Aug; 148(33-34):57. PubMed ID: 16981393
    [No Abstract]   [Full Text] [Related]  

  • 9. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Wiedermann CJ
    Lancet; 2002 Jun; 359(9324):2199; author reply 2203-4. PubMed ID: 12091002
    [No Abstract]   [Full Text] [Related]  

  • 10. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Bloom JM
    Lancet; 2002 Jun; 359(9324):2201; author reply 2203-4. PubMed ID: 12091005
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of losartan in hypertension without vascular disease.
    Messerli FH
    Ann Intern Med; 2004 Apr; 140(7):W29. PubMed ID: 15069010
    [No Abstract]   [Full Text] [Related]  

  • 12. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
    Fournier A; Oprisiu R; Andrejak M; Fernandez L; Achard JM
    JAMA; 2003 Feb; 289(6):700; author reply 701. PubMed ID: 12585946
    [No Abstract]   [Full Text] [Related]  

  • 13. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
    Messerli FH; Grossman E; Fournier A
    JAMA; 2003 Feb; 289(6):700-1; author reply 701. PubMed ID: 12585945
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atenolol is dead: long live beta-blockade.
    Cockcroft JR
    J Am Coll Cardiol; 2009 Jun; 53(22):2102; author reply 2106-7. PubMed ID: 19477365
    [No Abstract]   [Full Text] [Related]  

  • 16. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC; Westergaard B; Sehestedt T; Kjeldsen SE; Lindholm LH; Wachtell K; Devereux RB; Ibsen H; Nieminen MS; Dahlöf B; Olsen MH
    J Hypertens; 2012 Jun; 30(6):1252-9. PubMed ID: 22499288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
    Ann Intern Med; 2003 Aug; 139(3):I28. PubMed ID: 12899605
    [No Abstract]   [Full Text] [Related]  

  • 19. The LIFE Trial in 2004.
    Beevers DG
    J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
    [No Abstract]   [Full Text] [Related]  

  • 20. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
    MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.